Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

As a molecule, siRNA goes against just about every rule in the traditional drug discovery book. Compared with small molecules, siRNA is large, covered in negative charges, and doesn’t easily cro ...

Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA (siRNA) drug reduced Lp(a) levels compared to placebo at ...

The GalNAc technology will be used in the first two agreements, combining it with two small ... siRNA therapies, and known for its effectiveness in reaching liver cells. Several US Food and Drug ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk ...

ranging from extension of drug plasma half-life to the delivery of heavily charged macromolecules, such as small interfering RNA (siRNA), across biological membranes into cells. The membrane ...

In a recent publication in Cell Reports Medicine, a collaborative research team led by Chen-Yu Zhang and Huan Wang at Nanjing ...

Materials & Methods: The NDS consisted of cationic liposomes (carrier, 100–140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump ...

Prof. Dr. Olivia Merkel, Professor of Drug Delivery, explained: “Nanoencapsulation is a highly efficient way to deliver siRNA to targets across the cellular membrane, protecting it from degradation ...